

August 9, 2016

The Manager – Listing
BSE Limited,
1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange plaza, 5th Floor, Plot No.C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir(s),

Sub: Outcome of the Board Meeting held on Tuesday, August 9, 2016

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

At the Board Meeting of the Company held on Tuesday, August 9, 2016, the Board of Directors considered and approved the Unaudited Financial Results of the Company for the first quarter ended June 30, 2016. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated August 9, 2016 are enclosed herewith.

Please take the same on record.

Thanking you,

for **AstraZeneca Pharma India Limited**


Anantha Murthy N
Legal Counsel & Company Secretary

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
Financial results for the quarter ended 30 June 2016

Part I	Rs in lakhs (except for number of shares)				
Statement of unaudited results for the quarter ended 30 June 2016					
SI No.	Particulars	3 months ended 30/06/2016 (Unaudited)	3 months ended 31/03/2016 (Audited) ⁴	3 months ended 30/06/2015 (Unaudited)	Year ended 31/03/2016 (Audited)
1	Income from operations				
	a) Net sales/ income from operations (net of excise duty)	13,809.23	13,351.48	12,003.12	52,645.98
	b) Other operating income	144.85	2,530.56	1,194.56	3,727.25
	Total income from operations (net)	13,954.08	15,882.04	13,197.68	56,373.23
2	Expenses				
	(a) Cost of materials consumed	319.83	868.74	920.10	3,475.85
	(b) Purchase of stock-in-trade	5,077.90	4,821.39	3,130.79	15,888.71
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(922.85)	(521.24)	592.42	541.52
	(d) Employee benefits expense	4,232.54	5,086.01	3,852.29	16,934.52
	(e) Depreciation and amortisation expense	406.89	423.71	428.35	1,742.64
	(f) Selling, marketing and distribution	1,264.93	2,234.57	2,001.93	7,194.29
	(g) Other expenses	2,384.60	3,071.95	2,171.46	10,696.60
	Total expenses	12,763.84	15,985.13	13,097.34	56,474.13
3	Profit/ (loss) from operations before other income, finance costs and exceptional items (1-2)	1,190.24	(103.09)	100.34	(100.90)
4	Other income	156.20	209.29	171.31	677.27
5	Profit/ (loss) from ordinary activities before finance costs and exceptional items (3+4)	1,346.44	106.20	271.65	576.37
6	Finance costs	-	-	-	-
7	Profit/ (loss) from ordinary activities after finance costs but before exceptional items (5-6)	1,346.44	106.20	271.65	576.37
8	Exceptional items	-	-	-	-
9	Profit/ (loss) from ordinary activities before tax (7+8)	1,346.44	106.20	271.65	576.37
10	Tax expense	289.63	50.47	-	50.47
11	Net profit/(loss) from ordinary activities after tax (9-10)	1,056.81	55.73	271.65	525.90
12	Extraordinary Item	-	-	-	-
13	Net profit/(loss) for the period (11-12)	1,056.81	55.73	271.65	525.90
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year				15,101.43
16	Basic and diluted earnings per share (of Rs 2 each) [not annualised] See accompanying note to the Financial Results	4.23	0.22	1.09	2.10

Notes:

- The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 9 August 2016.
- The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. 'Others' comprise service income pertaining to clinical trials.
- AstraZeneca Pharmaceuticals AB, Sweden, the promoter of the Company vide its letter dated 1 March 2014, had proposed voluntary delisting of equity shares from stock exchanges ('Delisting Proposal'). The Board of Directors of the Company at their meeting held on 15 March 2014, had accorded approval for the Delisting Proposal. Further, the Delisting Proposal has been approved by the requisite majority of shareholders of the Company as required under Regulation 8 of SEBI (Delisting of Equity Shares) Regulations, 2009. Securities Exchange Board of India (SEBI) in its Order dated 24 June 2014 has issued directions to Bombay Stock Exchange and National Stock Exchange to closely monitor the entire delisting process of the Company and the Company shall finally purchase shares from the public shareholders in the delisting offer only after seeking approval from Bombay Stock Exchange and National Stock Exchange. The Company has received in-principle approval of National Stock Exchange and Bombay Stock Exchange, for voluntary delisting of equity shares from the said exchanges. A writ petition had been filed by two shareholders of the Company before the Honourable High Court of Judicature at Bombay ("the Court"), seeking inter-alia an order from the Court, restraining the Company and AstraZeneca Pharmaceuticals AB, Sweden ("AZPAB") from implementing the Delisting Proposal. The Court which heard the petition on 8 October 2014 has disposed off the same, with the directions that the Petitioners as well as the Company and AZPAB are at liberty to prefer appeal against SEBI Order dated 24 June 2014, to the Securities Appellate Tribunal (SAT), within six weeks and until the SAT hears and disposes of the Petitioners' appeal, the Company and AZPAB shall not take any further steps in the process of delisting of equity shares of the Company. The SAT was requested to hear and decide the appeals as expeditiously as possible and preferably by 28 February 2015. Further, an appeal has also been filed by two shareholders of the Company before the SAT, Mumbai, against part of SEBI's Order dated 24 June 2014, in relation to Delisting Proposal. The case was posted for hearing on multiple dates during the year ended 31 March 2015. At the hearing held on 5 May 2015, the SAT posted the matter to be heard on 9 July 2015 which was subsequently rescheduled for hearing on 11 August 2015. In the final hearing held on 11 September 2015, the SAT has disposed off the appeal directing SEBI to complete the investigation within a period of six months from date of its order and pass appropriate order on merits. The SAT has further directed the Company and the Promoter not to proceed with the delisting of equity shares till the completion of investigation and passing of the above mentioned order on merits by SEBI. Also the SAT has directed the Company and the Promoters that if the order passed by SEBI on merits is adverse to the appellants, then the said order shall not be given effect to from the date of passing the said order till it is communicated to the appellants and four weeks thereafter.
- The figures for the preceding quarter ended 31 March 2016 as reported in this financial results are the balancing figures between audited figures in respect of the full previous year and the published year to date figures upto the end of the third quarter of the previous financial year. Also figures upto the third quarter of the relevant financial year were only reviewed and not subjected to audit. The above statement of financial results has been reviewed by the statutory auditors. The statutory auditors have issued an unqualified review report. The review report has been filed with the stock exchange and is also available on the Company's website.

Mumbai
Dated: 9 August 2016

By Order of the Board of Directors
For AstraZeneca Pharma India Limited


Sanjay Murdeshwar,
Managing Director

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
Segment wise revenue, results and capital employed

(Rs in lakhs)

Sl.no.	Particulars	3 months ended 30/06/2016 (Unaudited)	3 months ended 31/03/2016 (Audited) ²	3 months ended 30/06/2015 (Unaudited)	Previous year ended 31/03/2016 (Audited)
1	Segment revenue				
	(a) Healthcare	13,594.34	15,438.15	13,055.22	55,402.82
	(b) Others	359.74	443.89	142.46	970.41
	Net sales/income from operations	13,954.08	15,882.04	13,197.68	56,373.23
2	Segment results				
	Profit/(loss) before tax and interest				
	(a) Healthcare	1,179.15	(113.27)	94.28	(135.16)
	(b) Others	11.09	10.18	6.06	34.26
	Total	1,190.24	(103.09)	100.34	(100.90)
	Add: Other income	156.20	209.29	171.31	677.27
	Add: Exceptional item	-	-	-	-
	Less: Interest	-	-	-	-
	Total profit/(loss) before tax	1,346.44	106.20	271.65	576.37
3	Capital employed				
	(a) Healthcare	7,061.88	6,791.87	6,325.29	6,791.87
	(b) Others	(339.13)	(165.94)	(133.79)	(165.94)
	(c) Unallocated	9,935.49	8,975.50	9,155.68	8,975.50
	Total	16,658.24	15,601.43	15,347.18	15,601.43

Notes :

- 1 Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.
- 2 The figures for the preceding quarter ended 31 March 2016 as reported in this financial results is the balancing figure between audited figures in respect of the full previous year and the published year to date figures upto the end of the third quarter of the previous financial year. Also figures upto the third quarter of the relevant financial year were only reviewed and not subjected to audit.

B S R & Co. LLP

Chartered Accountants

Maruthi Info-Tech Centre
11-12/1 Inner Ring Road
Koramangala
Bangalore 560 071 India

Telephone: + 91 80 3980 6000
Fax: + 91 80 3980 6999

Review report to the Board of Directors of AstraZeneca Pharma India Limited

We have reviewed the accompanying statement of unaudited financial results ("Statement") of AstraZeneca Pharma India Limited ("the Company") for the quarter ended 30 June 2016. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this Statement based on our review. Attention is drawn to the fact that the figures for the quarter ended 31 March 2016 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures upto the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement for the quarter ended 30 June 2016 prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **B S R & Co. LLP**

Chartered Accountants

Firm Registration Number: 101248W/W-100022



Supreet Sachdev

Partner

Membership Number: 205385

Mumbai

9 August 2016